Matthew Perrone
KOTA Territory News
Washington, DC, United States
Contact Matthew
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Matthew:
US health officials approve closely watched Alzheimer’s drug
The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease’s underlying biology. → Read More
FDA finalizes rule allowing mail-order abortion pills
Tuesday’s action formally updates the drug’s labeling to allow women to get a prescription via telehealth consultation with a health professional, and then receive the pills through the mail, where permitted by law. → Read More
Juul reaches settlements covering more than 5,000 cases
Financial terms of the settlement were not disclosed, but Juul said that it has secured an equity investment to fund it. → Read More
Sleep apnea device recall drags on, stoking anger from users
Sound-dampening foam in the pressurized breathing machines can break down over time, leading users to potentially inhale tiny black particles or hazardous chemicals while they sleep, manufacturer Philips warned. → Read More
Many baby formula plants weren’t inspected because of COVID
The gap in baby formula plant inspections, brought on by the COVID-19 pandemic, is getting new scrutiny from Congress and government watchdogs investigating the series of missteps that led to the crisis. → Read More
Abbott restarts baby formula plant linked to contamination
The February shutdown of the largest formula factory in the country led to supply problems. → Read More
Biden offers logistics support to ease formula shortage
President Joe Biden is offering formula manufacturers and retailers transportation and logistics support to ease the nationwide shortage of baby formula. → Read More
EXPLAINER: What’s behind the baby formula shortage?
Many parents are hunting for infant formula after a combination of short- and long-term problems hit most of the biggest U.S. brands. → Read More
US begins offering 1 billion free COVID tests, but many more needed
The website, COVIDTests.gov, allows people to order four at-home tests per household and have them delivered by mail. But the tests won’t arrive for seven to 12 days. → Read More
Omicron may sideline two leading drugs against COVID-19
The rapidly-spreading omicron variant may soon leave U.S. doctors without two of the standard treatments they’ve used to fight COVID-19. → Read More
Pfizer confirms COVID pill’s results, potency versus omicron
Pfizer says that its experimental COVID-19 pill appears effective against the omicron variant. → Read More
US expands Pfizer COVID boosters, opens extra dose to age 16
On Thursday, the Food and Drug Administration gave emergency authorization for 16- and 17-year-olds to get a third dose of the vaccine made by Pfizer and its partner BioNTech -- if it’s been six months since their last shot. → Read More
New COVID-19 antibody drug OK’d to protect most vulnerable
The drug could benefit cancer patients, organ transplant recipients and people with severe allergies to vaccinations. → Read More
Final US hurdle for Merck’s COVID-19 pill: FDA panel review
The Food and Drug Administration is asking its outside experts whether the agency should authorize the pill, weighing new information that it is less effective than first reported and may cause birth defects. → Read More
FDA: Merck COVID pill effective; experts will review safety
The Food and Drug Administration posted its analysis of the pill ahead of a public meeting next week where academic and other experts will weigh in on its safety and effectiveness. → Read More
COVID-19 pill cut hospitalization, death by 90%, Pfizer says
Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months. → Read More
Pfizer says COVID-19 vaccine more than 90% effective in kids
Details of the study were posted online Friday as U.S. regulators consider opening vaccinations to youngsters 5 to 11. → Read More
FDA panel endorses booster shot for J&J COVID-19 vaccine
J&J has asked the Food and Drug Administration for flexibility with its booster, arguing the extra dose adds important protection as early as two months after initial vaccination - but that it might work better if people wait until six months later. → Read More
FDA authorizes first e-cigarettes, cites benefit for smokers
Heath officials have authorized the first electronic cigarettes in the U.S., saying the R.J. Reynolds vaping products can benefit adult smokers. → Read More
Next on FDA’s agenda: Booster shots of Moderna, J&J vaccines
On Thursday and Friday, the Food and Drug Administration convenes its independent advisers for the first stage in the process of deciding whether extra doses of the two vaccines should be dispensed and, if so, who should get them and when. The final go-ahead is not expected for at least another week. → Read More